Classification of Left Ventricular Systolic Dysfunction by Ejection Fraction
According to the 2022 AHA/ACC/HFSA guidelines, left ventricular systolic dysfunction is classified as: severe (LVEF ≤40%), mild (LVEF 41-49%), and normal/preserved (LVEF ≥50%). 1
Guideline-Based Classification
The most recent authoritative classification comes from the 2022 AHA/ACC/HFSA Heart Failure Guidelines, which defines three primary categories based on LVEF 1:
Severe LV Dysfunction (HFrEF)
- LVEF ≤40%
- This represents heart failure with reduced ejection fraction
- Most clinical trials demonstrating survival benefit have enrolled patients with LVEF ≤35% or ≤40%
- This category has the strongest evidence base for guideline-directed medical therapy
Mild LV Dysfunction (HFmrEF)
- LVEF 41-49%
- Termed "heart failure with mildly reduced ejection fraction"
- Patients in this range often represent a dynamic trajectory—either improving from HFrEF or deteriorating toward HFrEF
- Important caveat: One EF measurement at a single time point may be inadequate; trajectory over time is critical 1
- For diagnosis, clinical symptoms plus elevated natriuretic peptides or evidence of increased LV filling pressures should support the classification
Preserved LV Function (HFpEF)
- LVEF ≥50%
- Represents at least 50% of the heart failure population with increasing prevalence
- Requires additional objective measures beyond EF (elevated natriuretic peptides or hemodynamic evidence of increased filling pressures) to confirm diagnosis 1
Clinical Context and Prognostic Implications
The 35% threshold holds particular clinical significance beyond the guideline categories. Research demonstrates that the 35% LVEF cut-off provides better risk stratification than the 40% cut-off, with superior sensitivity and specificity for predicting all-cause and cardiovascular mortality 2. Both thresholds independently predict outcomes, but 35% shows more accurate discrimination.
Normal LVEF Reference Values
Recent meta-analysis of healthy populations establishes that the lower limit of normal LVEF is approximately 52-53% 3:
- Women: ~53% lower limit (mean 63.7%)
- Men: ~52% lower limit (mean 61.9%)
- An LVEF <50% is highly unlikely (<5% probability) to represent normal function regardless of sex or age 3
Common Pitfalls to Avoid
Single measurement reliance: For patients with LVEF 41-49%, do not base management on one measurement alone—assess trajectory over time 1
Assuming linearity: The relationship between LVEF and outcomes is not strictly linear. Interestingly, supranormal LVEF (>70%) may paradoxically associate with increased adverse events, possibly reflecting underlying pathology 4
Overlooking additional parameters: LVEF alone does not capture complete cardiac function. Consider diastolic function, right ventricular function, and congestion status for comprehensive risk assessment 5
ICD-10 coding discordance: Be aware that hypertensive heart disease codes (I11.0, I13.0, I13.2) show wide LVEF ranges and poor concordance with actual systolic function 6
Treatment Implications
The severity classification directly impacts therapeutic decisions:
- LVEF ≤35-40%: Strong evidence for neurohormonal blockade, device therapy eligibility (ICD, CRT)
- LVEF 41-49%: Emerging evidence suggests potential benefit from HFrEF therapies, though less robust 7
- LVEF ≥50%: Focus on comorbidity management; no proven mortality-reducing therapies to date 8
Response to therapy (such as CRT) occurs across all LVEF ranges in eligible patients, with no lower LVEF limit predicting non-response 9, emphasizing that very low LVEF should not exclude patients from guideline-directed therapies.